Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. (Q40392114)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

Asher A Chanan-Khan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Raymond J Hohl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Todd M Zimmerman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Neal P Christiansen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Gary J Schiller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

John Lister

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Martin Oken

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sundar Jagannath

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

559-565

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

BCL2 family of apoptosis-related genes: functions and clinical implications in cancer

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Bcl-2 antisense therapy in B-cell malignant proliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902748971

10.1080/10428190902748971

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19373653%20AND%20SRC:MED&resulttype=core&format=json